Arecor welcomes discussion with Mrs Kemi Badenoch, MP for Saffron Walden


Arecor welcomed Mrs Kemi Badenoch, MP for Saffron Walden, to its offices at Chesterford Research Park.

Read More

Lonza Pharma & Biotech chooses Chesterford Research Park to expand UK operations


Lonza signs 15-year lease of the 42,000 sq ft Gonville Building at Chesterford Research Park.

Read More

Isomerase secures first pre-let within the Newnham Building


Chesterford Research Park is delighted to confirm that Isomerase will take up occupancy within Suite 4 of the Newnham Building upon its completion in mid 2020.

Read More

Synthetic biology gets a makeover with Evonetix’s DNA synthesis technology


Interview with Matthew Hayes, CTO and Co-Founder, Evonetix

Read More

Boston research firm leads the charge to Cambridge


Property adviser Savills reports a fresh surge of interest in Cambridge from American companies and investors.

Read More

Global double whammy for fast-growing Arecor


A global top 20 pharmaceutical giant is leveraging proprietary formulation technology from Arecor, the Chesterford Research Park-based company.

Read More

Two honey bee hives arrive at Chesterford Research Park’s new apiary


20,000 honey bees have a new home at the Park after three members of the team passed their bee-keeping course with flying colours!

Read More

Uttlesford District Council in running for award after investment in Chesterford Research Park


Uttlesford District Council's (UDC) entrepreneurial activities have been short-listed for two major local government awards.

Read More

Domainex helping to develop potential new heart drug


Domainex scientists, working with Professor Michael Schneider and his team at Imperial College, have found a potential new drug for treating the damage caused by a heart attack by targeting the way the heart reacts to stress.

Read More

NodThera advances lead candidate and adds two big hitters to board


NodThera has advanced its lead development candidate, NT-0167, into pre-IND testing as it prepares to advance to the clinic.

Read More

Cambridge startups lead regional VC boom despite UK lull


More than £125 million ($163.4m) of Venture Capital investment was made into the startup community in the East of England in the first three months of the year.

Read More

First patient dosing in Phase 1 Clinical Trial of Ultra-Rapid Acting Insulin Product Candidate AT247 for Diabetes


Arecor today announces dosing of the first patient in its Phase 1 clinical trial for its ultra-rapid acting insulin product candidate, AT247.

Read More

CellCentric backed in blood cancers trials


CellCentric in Cambridge has received approval from the UK regulatory authority, the MHRA, to start clinical trials of its CCS1477 technology to treat certain blood cancers.

Read More

Arecor signs a new multi-product collaboration with a major global pharmaceutical company


Arecor today announces that it has signed a collaboration with a new major global pharmaceutical partner.

Read More

GrandOmics collaborates with Oxford Nanopore to deliver nanopore sequencing project dbSV-100k


Strategic collaboration represents largest nanopore sequencing project to date.

Read More

Chesterford Research Park companies make their mark in Business Weekly’s Killer50 rankings


Business Weekly has published its 2019 list of Cambridge’s most disruptive tech and life science companies, known as the ‘Killer50’.

Read More

Domainex and SpiroChem enter a fragment drug discovery partnership


Domainex Ltd have established a strategic fragment drug discovery collaboration that they will co-promote globally.

Read More

Arecor receives Regulatory Approval to Initiate Phase 1 Clinical Trial for Ultra-Rapid Acting Insulin Product


Arecor Ltd today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.

Read More

Arecor Appoints Chief Financial Officer


Arecor Limited is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect from 4th March 2019.

Read More

International Women’s Day activities at Chesterford Research Park focus on empowering women to return to work


Chesterford Research Park and Isogenica team up to host a clothing drive in aid of not-for-profit organisation, Dress for Success.

Read More

Super-fast-acting Prandial Insulin Product Receives £0.5m Innovate UK Boost


Arecor Ltd has been awarded a £0.5 million grant from Innovate UK to advance the Company's proprietary super-fast-acting prandial insulin product, AT270.

Read More

Business Weekly New Year Honours 2019


We're delighted to have been included in Business Weekly's New Year Honours Listing 2019. Discover where we placed in the following article.

Read More

Arecor Featured by Industry Publication SCRIP


Arecor Ltd is pleased to announce that a feature profile by the highly regarded industry publication, SCRIP, is now available on the news section of the company’s website.

Read More

Isogenica LlamdA VHH antibodies reported as a potential treatment of Wnt-hypersensitive tumours


Isogenica Ltd today announced the publication in Nature Communications of a promising new strategy for treatment of Wnt-hypersensitive tumours.

Read More

Evonetix appoints Stephanie Brooking as Head of Product Management


Evonetix Ltd today announced it has appointed Stephanie Brooking as Head of Product Management.

Read More

Illumina CEO talks $100 genome, tariffs and NovaSeq at JP Morgan


CEO Francis deSouza discusses the $100 genome, tariffs and NovaSeq and other topics during Illumina’s JP Morgan presentation and breakout session.

Read More

Arecor to participate at PEPTalk 2019 protein science week in San Diego


Arecor is pleased to announce its participation at PEPTalk 2019’s Protein Science Week, January 14018, 2019, San Diego, California, USA.

Read More

Arecor announce clinical trials application to conduct a Phase I clinical trial of its ultra rapid acting insulin product


Arecor has filed a Clinical Trial Application to conduct a Phase I study in Type 1 patients of its ultra-rapid acting insulin product, AT247.

Read More

Can Cambridge become the world's leading biotech cluster?


The fenland city has big plans for its £4.2bn life sciences hub, but without support it will struggle to match the scale of world-leader Boston.

Read More

Occupier Focus: Charles River Laboratories


From prestigious, bespoke HQ buildings, to the fully fitted laboratory space Chesterford Research Park offers biotechnology and pharmaceutical R&D companies modern, dynamic and flexible facilities.

Read More

Arecor successfully defends key European Patent


Arecor successfully defends a key European Patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage.

Read More

Spotlight on the Newnham Building


Occupying a prominent position on the park and within close reach of the Nucleus’ central facilities, the existing Newnham building is set to undergo an extensive programme of refurbishment.

Read More

Arecor secures £6m investment for clinical development of portfolio


Arecor today announces that it has secured £6.0 million of investment from new and existing investors for the clinical development.

Read More

Occupier focus: Arecor


One organisation which has been thriving at Chesterford is Arecor Limited, a leading formulation technology company.

Read More

Arecor presenting at the Bioprocessing Summit, Boston, MA


Arecor Ltd is pleased to announce its participation at the Bioprocessing Summit, 13th-17th August 2018, at the Sheraton Boston Hotel, Boston, Massachusetts, USA.

Read More

NodThera secures £28 million ($40 million) Series A Financing


NodThera today announces it has closed its Series A financing round for a total of £28 million ($40 million).

Read More

Arecor announces superfast insulin data


Arecor announces superfast insulin data presentations at the American Diabetes Association 78th Scientific Sessions.

Read More

Chesterford Research Park – positioned for success


Chesterford Research Park has established itself as a centre of excellence within the South Cambridge biotech cluster, providing a supportive and nurturing location for innovation.

Read More

US$1.3 MILLION* Grant awarded to Arecor & Manchester Institute of Biotechnology


Arecor Ltd is pleased to announce that the Company, in collaboration with the Manchester Institute of Biotechnology (“MIB”), has been awarded a £0.97 million grant from Innovate UK.

Read More

Arecor Patent Portfolio Update


Arecor Ltd has issued “Notice of Intention to Grant” for Arecor’s patent application protecting the Company’s proprietary technology used in the development of protein therapeutics.

Read More

A superb environment for both early stage and established R&D companies


Providing the very best flexible and future proofed environment for both established and early stage companies, Chesterford actively facilitates occupiers’ pursuit of their research.

Read More

Discover a new future at Chesterford Research Park


Chesterford Research Park provides a full range of facilities and an exceptional working environment for both established and early-stage pharmaceutical and R&D companies.

Read More

Arecor and JDRF announce successful pre-clinical development


Arecor and JDRF are pleased to announce the successful completion of their partnered programme to significantly enhance treatment of type 1 diabetes.

Read More

Arecor announces successful vaccine stabilising formulation technology


Arecor in partnership with GALVmed has successfully applied its vaccine formulation technology to stabilise liquid formulations of vaccines to combat two major diseases of livestock in the developing world.

Read More

Fundraising efforts raise over £700 for Children In Need!


The Park Team took fundraising for Children In Need incredibly seriously on Friday last week - dressing the part as well-known characters to raise money for Pudsey!

Read More

Isomerase celebrate presentation of Queen’s Award for Enterprise


Isomerase staff, guests and local dignitaries gathered to celebrate the organisation’s attainment of the Queen’s Award for Enterprise in International Trade.

Read More

Arecor strengthens patent portfolio


Arecor strengthens the patent portfolio of its formulation technology for the development of novel vaccine and gene therapy products.

Read More

TLIP provides Patent Strategy Workshop to Isogenica


TLIP has concluded a series of IP seminars for Isogenica, a company specialising in antibody discovery and other biologics using proprietary techniques.

Read More

Arecor announces license agreement with global pharmaceutical company


Arecor is pleased to announce that a global pharmaceutical and healthcare company, has exercised its license option to Arecor’s proprietary formulation technology, to develop differentiated biosimilar products.

Read More

Dr Sam Fazeli joins Arecor as Non-Executive Director


Arecor Ltd is pleased to announce the appointment of Dr Sam Fazeli, as Non-Executive Director of the Company.

Read More

Cambridge Epigenetix relocate to Chesterford Research Park


Specialists in the discovery of epigenetic biomarkers and the development of clinical diagnostic assays take up residence in the Trinity Building.

Read More

CellCentric exploring CCS1477 and p300/CBP inhibition for haematological cancers


CellCentric has signed an agreement with Columbia University Medical School, New York USA, to explore the relevance of the company’s drug Candidate, CCS1477, in treating certain haematological cancers.

Read More

Third place for Michael at World Championships!


All the training is clearly paying off as Michael placed third in the Sprint Duathlon World Championships in Penticton, Canada during the ITU Multipart World Championships Festival.

Read More

Axol enhances its future scientific & commercial endeavours


Axol Bioscience has received investment from private equity firm Calculus Capital, a leading EIS and VCT investor.

Read More

From Office Junior to Director...


Cathy Mack has been appointed Director and Chief Operating Officer (COO) of patent and trademark company, TLIP Ltd (Turnbull Lynch Intellectual Property).

Read More

Cabinet members ‘meet and greet’ Park lifescience organisations


Further to Uttlesford District Council’s recent purchase of a 50% share in Chesterford Research Park, members visited to tour the facilities of Arecor and Evonetix.

Read More

Isogenica announces renewal of licence agreement by Harpoon


Isogenica Ltd today announced that Harpoon Therapeutics is renewing the licence and option agreement originally signed with Isogenica in June 2016.

Read More

Uttlesford District Council purchase 50% share in Park


Local authority invests in prestigious development to become joint owners alongside Aviva Investors.

Read More

Isomerase win Queen's Award for Enterprise in International Trade


Isomerase staff, guests and local dignitaries gathered to celebrate the organisation’s attainment of the Queen’s Award for Enterprise in International Trade.

Read More

Evonetix take two suites within Science Village


The Start-up developing and commercialising a new approach to the synthesis of DNA has taken two suites in Science Village.

Read More

Isogenica: New licence agreement with top-25 global pharma company


Isogenica Ltd today announced a new licensing deal with a top-25 global pharmaceutical company which specialises in immunology, oncology and immuno-oncology biopharmaceuticals.

Read More

CellCentric’s novel p300/CBP inhibitor, CCS1477 advancing to the clinic


CellCentric has developed a potent, selective, orally bioavailable small molecule inhibitor of p300/CBP.

Read More

Isogenica announce new licensing deal with Maverick Therapeutics


Science Village based Isogenica Ltd today announced a new licensing deal with Maverick Therapeutics.

Read More

Arecor awarded £1.05M from Innovate UK


Arecor Ltd is pleased to announce that it has been awarded a £1.05 million grant from InnovateUK.

Read More

Enplas takes a suite within Science Village


The Cambridge Enplas Life Science Laboratory, part of Enplas EU Ltd, a wholly owned subsidiary of Enplas Corporation have taken a five-year lease within the Park’s Science Village.

Read More

CamNet Data Communications relocate to Park


Local data communications company moves to Chesterford to fuel future growth.

Read More

Arecor confirms move to Chesterford Research Park


Chesterford Research Park attracts leader in formulation technology innovation, Arecor, to the Park.

Read More

Chesterford Research Park proves ideal new home for Domainex


Provider of integrated drug discovery services benefits from enhanced space within the Churchill Building.

Read More

Mat Leese joins specialist European Patent Attorney, TLIP


Mat joins TLIP as a UK and European Patent Attorney and has particular expertise in securing additional terms of protection for therapeutic products.

Read More

Axol Bioscience sign collaboration agreement with Metrion Biosciences


The agreement aims to improve, standardise and more accurately predict the risk of human clinical proarrhythmias.

Read More

RPC take on further space within the Mansion House to support growing team


Insurance sector specialists RPC Consulting take on further space within the Mansion House to support growing actuarial software team.

Read More

DRW's Helen Lee wins EPO European Inventor of the year award!


Congratulations to Dr Helen Lee of DRW who has been awarded the European Inventor Award by the European Patent Office.

Read More

Michael wins Bronze at European Duathlon Champs!


Congratulations to Michael Buchallet, who finished third in his age group at the European Duathlon (sprint) Championships in Germany last Saturday!

Read More

Park plants 2000 poppies to celebrate work of Royal British Legion


Joined by the Mayor of Saffron Walden, Park occupiers, staff and guests help to plant a new poppy and wildflower meadow at Chesterford Research Park.

Read More

Axol Bioscience appoints Paul Andrews to Scientific Advisory Board


Axol Bioscience today announced Paul Andrews as their Scientific Advisory Board Member.

Read More

Steve Rees joins Axol Bioscience Scientific Advisory Board


Axol Bioscience have announced that Steve Rees of AstraZeneca will join their Scientific Advisory Board (SAB).

Read More

Axol Bioscience re-locate to Chesterford to facilitate future growth


The stem cell disease model specialists join Chesterford’s Science Village community, taking space within the Park’s prestigious, ‘plug and play’ laboratory accommodation.

Read More

Collaboration with Cambridge Enterprise highlights thriving life science community


Over 70 top academics from Poland visited the Park as part of nine week ‘Top 500 Innovators’ programme.

Read More

Oncologica's success drives expansion at the Park


Oncologica take a further suite within The Science Village, Chesterford’s high quality, prestigious self-contained accommodation.

Read More

The European patent and trademark attorney joins Mansion House


Chesterford Research Park is delighted to welcome TLIP (Turnbull Lynch Intellectual Property) to the Park.

Read More

Park sponsored duathlete, Michael Buchallet, competes in Spain


Michael ran strongly over the first 5km before coming in to collect his bike for two laps of the difficult course.

Read More

Oncologica choose Chesterford Research Park as location for new HQ


The Contract Research and Diagnostic Services organisation take a suite in Science Village, Chesterford’s high quality, prestigious self-contained accommodation.

Read More

Park backs Team GB Duathlete, Michael Buchallet


Park’s health and fitness centre, situated within The Nucleus central facilities building at the heart of the Park, offers Michael training support.

Read More

Chesterford Research Park welcome Quantel to Science Village


Leading developer of innovative, high performance media content creation and delivery systems joins swiftly expanding Science Village community on the Park.

Read More

Park welcome Diagnostics for the Real World to Science Village


Leading developer and supplier of breakthrough point-of-care diagnostics is the latest company to take up occupancy within the Science Village Building.

Read More

Race to Lapland challenge inspires Nucleus gym members!


Race to Lapland challenge inspires Nucleus gym members!

Read More

Christmas comes early to Chesterford Research Park!


Despite the rain 75 Park tenants and members of the local community gathered at Chesterford Research Park this lunchtime to take part in a Santa Fun Run.

Read More

Chesterford Research Park Team out in force for Children in Need


Today the Park Team are once again dressed in their finest in support of Children in Need.

Read More

Isomerase Therapeutics expands presence within Science Village


Innovative drug discovery and development company take additional Suite within the Science Village Building.

Read More

Park helps raise over £3,000 for Addenbrooke’s Breast Cancer Appeal


Wednesday 1st October Chesterford Reseach Park played host to a very special fashion show in aid of Addenbrooke’s Breast Cancer Appeal.

Read More

Biofocus win Chesterford’s 5-a-side tournament


The team beat off stiff competition over the course of the tournament from Illumina, SBS, and Glassworks but ultimately came out on top.

Read More

Isogenica appoints new CEO


Isogenica have announced the appointment of Dr Chris Ullman as CEO with effect from September 29th 2014.

Read More

Marriott Sinclair move to Chesterford Research Park


Mathematical modelling company take remaining space within Garden Cottage.

Read More

Excitement as Tour de France cyclists pass through Chesterford!


Le Tour comes to Chesterford!

Read More

Carnival Celebrations at The Nucleus to mark local residents' 50th birthday!


All the fun and colour of the carnival came to The Nucleus last Saturday night to celebrate a local Little Chesterford residents’ 50th birthday.

Read More

Cambridge Architects Barber Casanovas Ruffles celebrate 30th year


Clients, colleagues and friends gather to mark leading architects 30th anniversary.

Read More

Retroscreen Virology to occupy Emmanuel Building at Chesterford Research Park


Antiviral research company, Retroscreen Virology has completed a deal to assign the entire Emmanuel building from current occupiers, Pfizer.

Read More

Park raises much needed funds for Teenage Cancer Trust


Chesterford Research Park held a pre-Christmas raffle, the proceeds of which will help the charity continue to support and educate young people affected by cancer and fund further research.

Read More

Construction underway for BioFocus’ new laboratory and HQ facility


BioFocus management team celebrate commencement of works with first site visit.

Read More

Greentech technology company Cellulac move into the Science Village


The Park has welcomed yet another innovator, this time to Science Village. Cellulac, a ‘greentech’, carbon neutral technology company has taken Suite 4 (1,515 sq ft) on a five year lease.

Read More

Celebrity Chef Anton Edelmann delights Park guests with Autumnal celebration


Commercial agents, Park tenants, Investors, joint developers of the Park, as well as special guests from Elior, the Park’s contract caterers, gathered at The Nucleus for an evening of exceptional gourmet food and fine wines.

Read More

Saffron Building Society expands to Chesterford


A former engineering building at Chesterford Research Park has been converted and renovated to provide a new home for the Contact Centre team from Saffron Building Society.

Read More



William Clarke, Savills
Email me


Amanda Newman, Events Executive
Email me


Katherine Maguire, Park Manager
Email me